Arghavani mohammad (9 Ergebnisse)

Zustand: New.

Zustand: As New. Unread book in perfect condition.

Zustand: New.

Zustand: As New. Unread book in perfect condition.

Paperback. Zustand: new. Paperback. Antibody Empire opens the BioLionaire Scientist series with a deep exploration of how monoclonal antibodies evolved from academic immunology experiments into one of the most powerful therapeutic platforms in modern medicine.This volume examines the scientific breakthroughs, engineering refinements, clinical turning points, and strategic decisions that transformed antibodies into a multi-hundred-billion-dollar global industry. Rather than presenting a simplified success narrative, the book analyzes the real mechanisms behind platform creation - from hybridoma technology and recombinant engineering to immune checkpoint modulation and translational funding pathways.Through detailed scientific discussion and strategic analysis, the book demonstrates how curiosity-driven laboratory discoveries matured into dominant oncology and autoimmune therapeutics. It connects molecular immunology to manufacturing scale, patent protection, regulatory positioning, and capital formation.This is a scientifically rigorous guide for researchers who want to understand not only how antibodies work - but how therapeutic empires are built.Who This Book Is ForThis volume is written for graduate students, postdoctoral researchers, clinician-scientists, biotechnology founders, translational investigators, and professionals seeking a deeper understanding of biologics strategy. It is equally suited for academic libraries, research institutions, and innovation-focused biotech teams.What This Book CoversThe book explores the biological foundations of antibody specificity, immune recognition, and monoclonal antibody development. It then moves into the engineering era - including humanization, Fc optimization, bispecific formats, and antibody-drug conjugates.Major oncology case studies such as CD20 targeting, HER2-directed therapy, CTLA-4 blockade, and PD-1 immune checkpoint modulation are analyzed not only for their biological significance, but for their strategic and commercial implications.Later chapters address manufacturing scalability, quality control systems, patent architecture, translational grant funding, SBIR mechanisms, startup formation, and biotech valuation frameworks.The volume closes by synthesizing scientific innovation with execution strategy - outlining the BioLionaire blueprint for platform dominance.Table of ContentsPart I - The Science of AntibodiesChapter 1 - Antibody BasicsChapter 2 - Monoclonal AntibodiesChapter 3 - Engineering the FuturePart II - From Bench to BlockbusterChapter 4 - The First Billion-Dollar AntibodiesChapter 5 - The Immuno-Oncology EraChapter 6 - Antibodies Beyond CancerPart III - The Business of AntibodiesChapter 7 - Anatomy of a Blockbuster DealChapter 8 - The Biotech PlaybookChapter 9 - Manufacturing and the Money PipelinePart IV - Future Antibody EmpireChapter 10 - Next-Gen AntibodiesChapter 11 - Deep learning for antibody designChapter 12 - Building Your Own Antibody PathChapter 13 - Approaching Funding BodiesAppendicesAppendix A - Antibodies Discussed in Antibody EmpireAppendix B - Sample K99/R00 NIH ProposalAppendix C - Common Antibody CROsAppendix D - How to Choose a CROGlossaryIndexCompanies & Platforms Discussed in this VolumeEssential Reading This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

Zustand: New. Print on Demand.

PAP. Zustand: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

PAP. Zustand: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

Paperback. Zustand: new. Paperback. Antibody Empire opens the BioLionaire Scientist series with a deep exploration of how monoclonal antibodies evolved from academic immunology experiments into one of the most powerful therapeutic platforms in modern medicine.This volume examines the scientific breakthroughs, engineering refinements, clinical turning points, and strategic decisions that transformed antibodies into a multi-hundred-billion-dollar global industry. Rather than presenting a simplified success narrative, the book analyzes the real mechanisms behind platform creation - from hybridoma technology and recombinant engineering to immune checkpoint modulation and translational funding pathways.Through detailed scientific discussion and strategic analysis, the book demonstrates how curiosity-driven laboratory discoveries matured into dominant oncology and autoimmune therapeutics. It connects molecular immunology to manufacturing scale, patent protection, regulatory positioning, and capital formation.This is a scientifically rigorous guide for researchers who want to understand not only how antibodies work - but how therapeutic empires are built.Who This Book Is ForThis volume is written for graduate students, postdoctoral researchers, clinician-scientists, biotechnology founders, translational investigators, and professionals seeking a deeper understanding of biologics strategy. It is equally suited for academic libraries, research institutions, and innovation-focused biotech teams.What This Book CoversThe book explores the biological foundations of antibody specificity, immune recognition, and monoclonal antibody development. It then moves into the engineering era - including humanization, Fc optimization, bispecific formats, and antibody-drug conjugates.Major oncology case studies such as CD20 targeting, HER2-directed therapy, CTLA-4 blockade, and PD-1 immune checkpoint modulation are analyzed not only for their biological significance, but for their strategic and commercial implications.Later chapters address manufacturing scalability, quality control systems, patent architecture, translational grant funding, SBIR mechanisms, startup formation, and biotech valuation frameworks.The volume closes by synthesizing scientific innovation with execution strategy - outlining the BioLionaire blueprint for platform dominance.Table of ContentsPart I - The Science of AntibodiesChapter 1 - Antibody BasicsChapter 2 - Monoclonal AntibodiesChapter 3 - Engineering the FuturePart II - From Bench to BlockbusterChapter 4 - The First Billion-Dollar AntibodiesChapter 5 - The Immuno-Oncology EraChapter 6 - Antibodies Beyond CancerPart III - The Business of AntibodiesChapter 7 - Anatomy of a Blockbuster DealChapter 8 - The Biotech PlaybookChapter 9 - Manufacturing and the Money PipelinePart IV - Future Antibody EmpireChapter 10 - Next-Gen AntibodiesChapter 11 - Deep learning for antibody designChapter 12 - Building Your Own Antibody PathChapter 13 - Approaching Funding BodiesAppendicesAppendix A - Antibodies Discussed in Antibody EmpireAppendix B - Sample K99/R00 NIH ProposalAppendix C - Common Antibody CROsAppendix D - How to Choose a CROGlossaryIndexCompanies & Platforms Discussed in this VolumeEssential Reading This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.…